Briumvi
(Ublituximab)
Provider Summary
Primary Uses
Relapsing forms of multiple sclerosis in adults per label/payer criteria.
Mechanism of action
Anti‑CD20 monoclonal antibody → B-cell depletion.
Pre-treatment / baseline requirements
Screen for active infection; TB screening (IGRA/PPD) and hepatitis B screening are commonly required for many biologics; baseline CBC and CMP/LFTs are often requested; review vaccination status (avoid live vaccines during therapy per PI); confirm pregnancy status when clinically appropriate; review prior biologic exposure and infection history. For anti‑CD20 therapies: HBV screening and baseline immunoglobulins are commonly requested; update vaccines before initiation when possible.
Common side effects
Infusion reactions, infections (e.g., upper respiratory), headache.
Serious adverse effects / key risks
Serious infections including HBV reactivation; PML (rare but class concern); infusion reactions; hypogammaglobulinemia over time.
Referral requirements
Standard infusion referral form + drug-specific checklist
Patient & Caregiver Education
What it treats
Relapsing forms of multiple sclerosis in adults
How it works
Targets CD20 on B-cells to reduce harmful immune activity
Before treatment
Tell your clinician if you have an active infection/fever, are pregnant/planning pregnancy, or have major heart/nerve problems. Depending on the medication, you may need labs or screening tests (e.g., TB/hepatitis) and a vaccine review
Common side effects
Infusion reactions, infections, headache.
Get urgent help for
Serious infections including HBV reactivation; PML; infusion reactions; hypogammaglobulinemia over time.
On treatment day
Plan to stay for monitoring. If you feel dizzy, drowsy, or unwell afterward, do not drive and follow your clinician’s instructions.